Endocrine Flashcards
(188 cards)
1
Q
Type 1 Diabetes Mellitus definition
A
Metabolic autoimmune destruction of pancreatic beta cells leading to complete insulin deficiency
2
Q
Type 1 diabetes epidemiology
A
5-15yrs
3
Q
T1DM aetiology
A
HLA-DR and HLA-DQ provide protection from or increase susceptibility to diabetes. Environmental factors and viruses may trigger the destruction of beta cells
4
Q
T1DM risk factors
A
geographic region (European > Asian), genetic predisposition, infectious agents, dietary factors
5
Q
T1DM pathophysiology
A
Autoimmune destruction of beta cells in the Islets of Langerhans by autoantibodies -> insulin deficiency and continued breakdown of liver glycogen -> hyperglycaemia and glycosuria
6
Q
T1DM key presentations
A
polyuria, polydipsia, blurred vision, fatigue or tiredness
7
Q
T1DM signs
A
young age (<50), weight loss, low BMI, FHx of autoimmune disease, ketoacidosis
8
Q
T1DM symptoms
A
thirst, dry mouth, lack of energy, blurred vision, hunger, weight loss
9
Q
T1DM 1st line investigations
A
Random glucose tolerance test >11.1mmol/L
Fasting plasma glucose, 2-hour plasma glucose, plasma or urine ketones can all be measured
10
Q
T1DM gold standard investigations
A
Glycated haemoglobin A1C test: average blood sugar for past 2-3 months, measures % glucose attached to Hb. >6.5% = diabetes
11
Q
T1DM differential diagnosis
A
Type 11 DM, other diabetes subtypes
12
Q
T1DM management
A
basal-bolus insulin; pre-meal insulin correction dose; amylin analogue; 2nd line: fixed insulin dose
13
Q
Side effects of insulin
A
hypoglycaemia; weight gain; lipodystrophy
14
Q
T1DM monitoring
A
Check BP at each visit and treat it to a goal of <140/90mmHg
15
Q
T1DM complications
A
Microvascular - retinopathy, nephropathy, neuropathy
Macrovascular - CAD (coronary artery disease), cerebrovascular disease, PAD (peripheral artery disease)
16
Q
T1DM prognosis
A
Untreated type 1 is fatal due to diabetic ketoacidosis.
Blindness, renal failure, foot amputations, MIs
17
Q
Type 2 Diabetes Mellitus definition
A
progressive disease characterised by high blood sugar, insulin resistance and a relative lack of insulin
18
Q
T2DM epidemiology
A
Around 90% of diabetes cases, around 6% of pop in England, around 10% of NHS expenditure
19
Q
T2DM aetiology
A
genetic predisposition (near 100% concordance in identical twins)
20
Q
T2DM risk factors
A
ageing, physical inactivity, overweight, obesity, M>F
21
Q
T2DM pathophysiology
A
Impaired insulin action leads to: reduced muscle and fat uptake after eating, failure to suppress lipolysis and high circulating FFAs and abnormally high glucose output after a meal.
Excessive glucose production due to hepatic insulin resistance possible due to fat deposition in liver and pancreas. This causes hyperglycemia.
Glycosuria due to hyperglycaemic blood.
Insulin suppresses lipolysis so increased FFAs in blood.
Even low levels of insulin prevent muscle catabolism and ketogenesis so profound muscle wasting and gluconeogenesis are restrained and ketone production is rarely excessive.
22
Q
T2DM signs and symptoms
A
usually asymptomatic (maybe glycosuria or high blood glucose) but can develop signs of hyperglycaemia (polyuria, polydipsia if severe)
23
Q
T2DM 1st line investigations
A
HbA1c: usually every 3 months, 48mmol/mol (6.5%) or greater
Fasting plasma glucose: 8hr min fast. Confirm an elevated result with HbA1c and second fasting plasma glucose, >6.9mmol/L (>125mg/dL)
Random plasma glucose: convenient but less accurate. Used for rapid assessment of glucose. >11.1mmol/L (greater than or >200mg/dL)
24
Q
T2DM gold standard investigations
A
2hr post-load glucose after 75g oral glucose: diabetes should be confirmed on separate occasion with another test. >11.1mmol/L (>200mg/dL)
25
Other T2DM investigations
Fasting lipid profile; urine ketones; random C-peptide; urinary albumin; serum creatinine and estimated GFR; ECG; ankle-brachial index; dilated retinal examination
26
T2DM differential diagnosis
pre-diabetes; T1DM; gestational diabetes; latent autoimmune diabetes in adults
27
T2DM management
Diet: low carbohydrates and reduced sugar. Remission may occur with significant sustained weight loss; moderate exercise and strength training.
Cardiovascular risk management: ACE inhibitors, Ca channel blocker, or thiazide diuretic if HTN present. Home BP monitoring.
28
T2DM complications
Microvascular: diabetic neuropathy (leg), diabetic retinopathy (eye), diabetic nephropathy (kidney).
Microvascular: storke, MI
29
T2DM prognosis
Risk of MI x2
| T2DM diagnosed at 40yrs men lose an average of 5.8yrs of life and women lose 6.8
30
Ketoacidosis definition
an acute metabolic complication of diabetes. An absolute insulin deficiency. Most common acute hyperglycaemia complication of T1DM.
Triad of hyperglycaemia, ketonaemia and metabolic acidosis with rapid symptom onset
31
Ketoacidosis epidemiology
Increasing for T2DM in UK
32
Ketoacidosis aetiology
Reduction in net effective concentration of circulating insulin and elevation in counter-regulatory hormones (glucagon, catecholamines, cortisol). Common causes are MI, sepsis and pancreatitis
33
Ketoacidosis risk factors
Drugs affecting carbohydrate metabolism such as corticosteroids, thiazides, cocaine and cannabis.
SGLT2 inhibitors have been indicated.
34
Ketoacidosis pathophysiology
Complete absence of insulin -> unrestrained increased hepatic gluconeogenesis and decreased peripheral glucose uptake. Hyperglycaemia -> osmotic diuresis -> dehydration.
Peripheral lipolysis -> increased FFA -> oxidised to Acetyl CoA -> ketones
= ACIDOSIS
35
Ketoacidosis key presentations
emergency admission
36
Ketoacidosis signs and symptoms
nausea and vomiting, abdominal pain, dehydration, hyperventilation, reduced consciousness, acetone smell on breath
37
Ketoacidosis 1st line investigations
```
venous blood gas: (pH>7 indicated mild-moderate DKA, pH<7 severe)
Blood ketones
Blood glucose
U&Es: mostly for potassium levels
FBC: leukocytosis
```
38
Ketoacidosis other investigations
Urinalysis, ECG, pregnancy test, amylase and lipase, cardiac enzymes, creatinine kinase, CXR, LFTs, cultures
39
Keotacidosis differential diagnosis
1. Hyperosmolar hyperglycaemic state (HHS)
2. Lactic acidosis
3. Starvation ketosis
4. Alcoholic ketoacidosis
5. Salicylate poisoning
6. Ethylene glycol/methanol intoxication
7. Uraemic acidosis
40
Ketoacidosis management
1. Start IV fluids as soon as DKA confirmed
2. IV potassium if hypokalaemic
3. Fixed rate IV insulin infusion
4. Continuous cardiac monitoring
41
Ketoacidosis monitoring
Hourly glucose and ketones, venous blood gas, CXR if SATS fall (pulmonary oedema)
42
Ketoacidosis complications
1. Hypokalemia
2. Hypoglycemia
3. Arterial or venous thromboembolic events
4. Cerebral oedema/brain injury
5. Pulmonary oedema/acute respiratory distress syndrome (ARDS)
6. Non-anion gap hyperchloremic acidosis
43
Ketoacidosis prognosis
Death is rare (0.67% mortality) prognosis is worse at extremes of age and in presence of coma and hypotension
44
Hyperosmolar hyperglycaemic state (HHS) definition
characterised by profound hyperglycaemia (glucose >30mmol/L) and volume depletion in the absence of significant ketoacidosis
45
HHS epidemiology
>1% of diabetes-related admissions
46
HHS aetiology
Occurs mostly in older T2DM patients. Most common causes are infections such as pneumonia and UTIs, acute illness such as MI or stroke or trauma. Can be seen in post op patients.
47
HHS pathophysiology
insulin is often higher than in DKA patient. Thought to be enough to suppress lipolysis and ketogenesis but not to regulate hepatic glucose production and promote glucose utilisation. Hypernatraemia and hyperglycaemia and inadequate water intake and loss result in hypovolaemia.
48
HHS key presentations
acute cognitive impairment. Consider foot infection
49
HHS signs and symptoms
Polyuria, polydipsia, weight loss, nausea and vomiting, weakness, dry mucous membranes, tachycardia, hypotension
50
HHS 1st line investigations
blood glucose, ketones, venous blood gas, serum osmolality, U&Es and creatinine, FBC, ECG
51
HHS differental diagnosis
DKA, alcohol ketoacidosis, paracetamol overdose, salicylate overdose, seizures, stroke
52
HHS management
fluid replacement and fixed-rate intravenous insulin. Correction of serum osmolality, electrolytes and blood glucose. Prevention of venous thromboembolism, complications of tremens and foot ulceration. Treatment of underlying cause
53
HHS monitoring
blood glucose; SATS; cardiac monitoring
54
HHS complications
Insulin-related hypoglycaemia; treatment related hypokalemia; MI; stroke; PE
55
HHS prognosis
high mortality (5-15%)
56
Grave's disease (hyperthyroidism) deifintion
most common cause of hyperthyroidism (75-80%) of cases. It is an autoimmune condition
57
Grave's disease epidemiology
predominantly females (20-30 years old)
58
Grave's disease aetiology
stimulation of the thyroid by TSH receptor antibodies. Caused mostly genetic but also environmental factors. Thyrotoxicosis is the clinical syndrome resulting from the effect of excess T3 and T4 in circulation. Overall is increased metabolic rate. Toxic adenoma is an example of another cause.
59
Grave's disease risk factors
more common in females, smoking, genetic: HLA-DR3 association; 50% have a family history of autoimmune disorders
60
Grave's disease pathophysiology
Grave's thyroiditis. Caused by an auto-antibody of the IgG class which binds to thyroid epithelial cells (TSH-receptor) and mimics the stimulatory actions of TSH. This antibody is known as thyroid stimulation antibodies and its effect on the thyroid is a hypersensitivity reaction. Thyroid cell dysfunction is cytotoxic (CD8+) T cell-mediated. The antibodies stimulate the function and growth of thyroid follicular epithelium. Some of the antibodies block the effects of TSH and rarely cause hypothyroidism.
61
Grave's disease key presentations
Diffuse goitre (equal swelling)
62
Grave's disease signs and symptoms
General for hyperthyroidism: heat intolerance (due to increase metabolism); sweating, hair loss; weight loss; diarrhoea; palpitations inc AF and tachycardia; tremor; anxiety and agitation; orbitopathy; menstrual and sexual disturbances.
Specific to grave's: Grave's opthalmopathy-exophthalmos, ocular motor disturbances, lid lag and retraction. Pretibial myxoedema (less common)- non-paying oedema and firm plaques on shins.
Classic triad of grave's: hyperthyroidism, opthalmopathy, pretibial myxedema.
63
Grave's disease 1st line investigations
Serum TSH. Levels will be low in hyperthyroidism.
Serum free or total T4: normal level with low TSH is suggestive of subclinical hyperthyroidism or T3 toxicosis. Elevated level with low TSH indicates overt hyperthyroidism.
Serum free or total T3: elevated free T3 and suppressed TSH suggest hyperthyroid.
T3/T4 or FT3/FT4 ratio: high ratio suggestive of grave's disease rather than thyroiditis.
Iodine uptake: diffuse uptake in Grave's
64
Grave's disease gold standard investigations
Measure TSH receptor antibodies
65
Grave's disease differential diagnosis
TSH producing pituitary tumour; toxic neck goitre; gestational hypethyroidism; subacute thyroiditis; menopause
66
Grave's disease management
First step is symptomatic treatment: beta blockers (propranolol first choice) to control tachycardia, sweating and tremors.
Antithyroid drugs: 12-18 month cause or to normalise levels before surgery. Includes carbimazole, thiamazole and propylthiouracil (PTU). Decrease synthesis of new thyroid hormone. PTU also inhibits T4 to T3 conversion. Do not treat underlying cause but immune modifying effects are seen (decreased IL-6).
Radioactive iodine therapy; surgery; immunosuppressive medication and steroids for opthalmopathy and pretibial myxoedema.
67
Grave's disease monitoring
monitor TSH levels after thyroxine replacement therapy following surgery or radioactive iodine therapy
68
Grave's disease complications
Thyroid storm - rare but dangerous exacerbation of hyperthyroidism. Need to use PTU, beta blockers, steroid (hydrocortisone) and potassium iodide
Bone mineral loss
AF
Congestive heart failure
Sight-threatening complications of Grave's orbitopathy
Elephantiasic demopathy
69
Grave's disease prognosis
excellent following therapy although there is a high degree of relapse
70
Hypothyroidism definition
underproduction og thyroid hormones thyroxine (T4) and triiodothyronine (T3)
Severe hypothyroidism is called Myxoedema
71
Hypothyroidism epidemiology
higher rates in white populations and in women (30-50yrs)
72
Hypothyroidism aetiology
can be congenital or acquired. Most common cause of congenital is iodine deficiency during pregnancy -> mental retardation and other defects
Most acquired hypothyroidisms are primary (95%) and due to Hashimoto's (Autoimmune thyroiditis) in developed countries.
Iodine deficiency most common cause in developing countries
Other primary causes include absence/dysfunction of thyroid
Can be due to surgery or iodine therapy for Grave's
Secondary/tertiary include pituitary/hypothalamic dysfunction
Consider drugs as cause (lithium and amiodarone)
73
Hypothyroidism risk factors
white, female, post-partum, iodine deficiency (much less common in the developed world)
74
Hypothyroidism pathophysiology
T4 is the main hormone produced by the thyroid. It is converted to T3 in target tissues. T3 stimulates cellular oxygen consumption and energy generation. Failure of the thyroid to produce T3 and T4 stimulates pituitary TSH production.
Hashimoto's thyroiditis is caused by infiltration of lymphocytes into the thyroid. (more info on Myles' table)
75
Hypothyroidism key presentations
usually present with non specific symptoms of weakness, lethargy, depression and mild weight gain.
Up to half of patients have no symptoms or no specific or no specific symptoms.
76
Hypothyroidism signs and symptoms
Symptoms: weakness, lethargy, depression, fatigue, hoarseness, cold sensation, constipation, weight gain, brittle hair, menstrual problems, erectile dysfunction, decrease libido, puffy face
Signs: slow speech and movement, dry skin, eyelid oedema, bradycardia, diastolic hypertension, myopathy, hyporeflexia
77
Hypothyroidism 1st line investigations
Primary hypothyroidism - thyroid function test (TFTs)
Raised TSH (most sensitive marker) and usually low free T4 and free T3
T4/T3 may be low/normal in mild hypothyroidism
Positive titre of TPO antibodies in Hashimoto's
Very low radio iodine uptake
Secondary/Tertiary Inappropriately low TSH for reduced T4/T3 levels
78
Hypothyroidism gold standard investigations
TFTs: TSH most sensitive
79
Hypothyroidism differential diagnosis
1. Central or secondary hypothyroidism
2. Depression
3. Alzheimer's
4. Anaemia
80
Hypothyroidism management
Levothyroxine (synthetic T4)
81
Hypothyroidism monitoring
Measure TSH 4-6 weeks after starting therapy or dosage change
Stable patients with normal serum TSH should have TSH measured every 12 months
82
Hypothyroidism complications
Complications in pregnancy
Myxoedema coma (severe hypothyroidism triggered by infections, surgery, trauma, illness; generally in the elderly)
Osteoporosis
AF (overtreatment)
Resistant hypothyroidism
Angina
Non-Hodgkin lymphoma - constant infiltration of lymphocytes in any organ/tissue increases the risk that those become cancerous
83
Hypothyroidism prognosis
generally excellent
84
Thyroid nodules/cancers definition
Nodules are benign tumours, cancers are malignant
4 main types of nodule:
1. Follicular Adenoma - most common; a benign tumour
2. Toxic adenoma - an adenoma which can secrete thyroid hormone independent of TSH (toxic)
3. Cysts - colloid filled sacks
4. MNG - multiple nodules which can secrete thyroid hormone; can also cause hyperthyroidism
4 main types based on histology of cancer:
1. Papillary carcinoma - most common
2. Medullary carcinoma
3. Follicular carcinoma
4. Anaplastic carcinoma - very bad prognosis
85
Thyroid nodules/cancers epidemiology
most common in females (increases with age)
Nodules present in 50% of population, only palpable in 5-10%
5% of all thyroid nodules are cancerous
86
Thyroid nodules/cancers risk factors
ionising radiation esp. in childhood
Genetic predisposition
age
female
87
Thyroid nodules/cancers signs and symptoms
```
Asymptomatic nodule
Nodule is firm and painless
Neck lymph nodes may be swollen
Tracheal deviation maybe present
Late-stage signs - dysphagia, dyspnea, hoarseness, SVC syndrome - local infiltration and mass effects
```
88
Thyroid nodules/cancers 1st line investigations
TSH level is usually normal
Ultrasound findings - nodule with irregular margins and micro-calcifications
FNA - indicated if ultrasound findings are suspicious
Tumour markers - thyroglobulin and calcitonin (medullary carcinoma as C cells are affected)
89
Thyroid nodules/cancers management
Surgery followed by radioactive iodine ablation plus TSH suppression with Levothyroxine (to prevent further growth)
90
Cushing's syndrome and Cushing's disease definitions
Cushing's syndrome is the clinical manifestation of pathological hypercortisolism (excess glucocorticoids) from any cause
Cushing's disease is hypercortisolism caused by an adrenocorticotropic hormone (ACTH) - screwing pituitary adenoma
91
Cushing's epidemiology
Relatively uncommon in general population.
| Both more common in women
92
Cushing's aetiology
Most common cause is exogenous corticosteroid exposure
A majority (70-80%) of endogenous Cushing's syndrome is caused by ACTH- secreting pituitary adenomas, this is Cushing's disease
Adrenal cortical neoplasms
Ectopic Cushing's syndrome due to paraneoplastic syndrome such as small cell lung cancer producing ACTH
93
Cushing's pathophysiology
Clinical manifestations result from excess tissue exposure to cortisol.
Excess glucocorticoids have a catabolic effect on skeletal muscle (muscle wasting) as well as catabolic effects on the epidermic and connective tissue (striae, easy bruising)
Decreased bone material density due to glucocorticoids causing increased apoptosis of osteoblasts and osteoclasts
Increased hepatic gluconeogenesis, peripheral insulin resistance and direct suppression of insulin occur
Glucocorticoids lead to increased VLDLs and LDLs and decrease in HDLs
Cortisol causes high insulin leading to weight gain
Hypertension due to up-regulation of RAS system
94
Cushing's signs and symptoms
Signs: weight gain (central obesity), purple abdominal striae, acne, hirsutism (facial and body hair in women), osteoporosis
Symptoms: mood change, proximal weakness, irregular menstruation, erectile dysfunction
95
Cushing's 1st line investigations
Careful drug history (oral steroids)
24hr free cortisol - normal levels help exclude Cushing's
Overnight dexamethasone suppression test - no cortisol suppression with Cushing's syndrome but no suppression with ectopic ACTH producing cells or adrenal adenoma
96
Cushing's differential diagnosis
May be difficult to distinguish between mild Cushing's and metabolic syndrome (central obesity with insulin resistance and HTN)
97
Cushing's management
Cushing's disease: first line is surgery to remove pituitary adenoma
Ectopic ACTH or corticotropin-releasing hormone syndrome: surgery
98
Cushing's complications
```
Adrenal insufficiency secondary to adrenal suppression
Cardiovascular disease
HTN
DM
Osteoporosis
Central hypothyroidism
```
99
Cushing's prognosis
Untreated has a 5 year survival of 50%
100
Acromegaly definition
Refers to the characteristic growth of extremities. It is a chronic, progressive, multi-systemic disease associated with significant morbidity and mortality.
Gigantism occurs in children with increase GH production, not adults
101
Acromegaly epidemiology
Pituitary adenomas occur in 15-20% of normal subjects
Growth hormone secreting tumours make up around 20% of pituitary tumours
Often recognised in middle-age but can occur at any age
NO difference between sexes
102
Acromegaly aetiology
Due to pituitary somatotroph (growth hormone producing cell) adenoma in 95-99% of cases
Rare cases due to hyperplasia eg ectopic GH-releasing hormone from a carcinoid tumour
103
Acromegaly pathophysiology
Growth hormone stimulates growth of bone and soft tissue through insulin-like growth factor 1
104
Acromegaly key presentations
Insidious (slow progression with few initial symptoms)
105
Acromegaly signs and symptoms
Acral enlargement - big hands and feet
Arthralgias (joint pain) and headaches
Facial features growth
Excessive swelling
Amenorrhea, decreased libido
Obstructive sleep apnoea (have they started snoring?)
Acroparenthesia (tingling in the extremities)
106
Acromegaly 1st line investigations
75g glucose tolerance test (if GH remains high after they receive glucose = diagnostic)
Serum insulin-like growth factor 1 (IGF-1)
107
Acromegaly gold standard investigations
Oral glucose tolerance test with 75g glucose
108
Acromegaly management
1st line: surgery
Somatostatin analogue - control GH and IGF-1 (somatostatin is also known as growth hormone inhibiting hormone (GHIH))
Dopamine agonists - cabergoline - used to control GH levels and IGF-1 GH antagonist
109
Acromegaly complications
Cardiac complications, HTN, sleep apnoea, osteoarticular complications, impaired glucose tolerance and diabetes, pre-concerous colon polyps, carpal tunnel syndrome
110
Conn's syndrome definition
Primary aldosteronism (PA), aldosterone production exceeds the body's needs
111
Conn's syndrome epidemiology
accounts for at least 5% of HTN patients with most being normokalaemic
112
Conn's syndrome aetiology
unknown for most forms. genetics
113
Conn's syndrome risk factors
HTN, family history of PA, family history of early onset of HTN and/or stroke
114
Conn's syndrome pathophysiology
Results in excessive Na+ reabsorption via amiloride-sensitive epithelial sodium channels in the distal nephron, leading to HTN and suppression of renin and angiotensin II. Urinary loss of K+ and H+, exchanged for sodium at distal nephron may result in hypokalaemia and metabolic alkalosis if severe and prolonged
115
Conn's syndrome key presentations
often asymptomatic
116
Conn's syndrome signs and symptoms
```
Signs of hypokalemia:
- weakness, cramps
- paraesthesia
- polyuria and polydipsia
- fatigue
- constipations
High BP, headaches, blurred vision, dizziness
```
117
Conn's syndrome 1st line investigations
U&Es
- serum hypokalaemia (not always present)
- decreased renin and increased aldosterone (aldosterone/renin ratio)
ECG: hypokalaemia
- flat T waves and inversion
- prolonged PR interval
- increased amplitude and width of P wave
- ST depression
- prominent U waves
- Long QT
118
Conn's syndrome differential diagnosis
Essential HTN
Secondary HTN
Thiazide induced hypokalemia in patient with essential HTN
119
Conn's syndrome management
Laparoscopic adrenalectomy
| Aldosterone agonist eg oral spironolactone 4 weeks pre op to control BP and K+
120
Conn's syndrome complications
AF, heart failure, MI, stroke
121
Adrenal insufficiency definition
insufficient production of steroid hormones (primarily cortisol) by the adrenal glands
122
adrenal insufficiency epidemiology
most common in middle aged females
123
adrenal insufficiency aetiology
Primary - mostly Addison's disease (autoimmune), idiopathic, congenital adrenal hyperplasia or adenoma of the adrenal gland
Secondary - hypopituitarism
TB is the most common cause worldwide
124
adrenal insufficiency pathophysiology
Addion's
Decreased production of adrenocortical hormones; mineralocorticoids (aldosterone), glucocorticoids (cortisol). Caused by destruction of the layers of the adrenal cortex (glomerulosa, fasciculate and reticular) or disruption of hormone synthesis. TB or metastasis can also cause destruction of the adrenal medulla
125
adrenal insufficiency key presentations
usually non-specific such as fatigue, weight loss and weakness
126
adrenal insufficiency signs and symptoms
Signs: pigmentation (not with secondary) and pallor, hypotension
Symptoms: fatigue, weight loss, poor recovery from illness, headache
127
adrenal insufficiency 1st line investigations
U&Es: low Na, high K
FBC: eosinophilia (high eosinophils), anaemia is common
Morning cortisol and ACTH
- low cortisol consistent with AI
- High ACTH indicates primary
- Low ACTH indicates secondary renin/aldo
- elevated renin in primary
128
adrenal insufficiency differential diagnosis
Adrenal suppression due to corticosteroid therapy (may have Cushingoid appearance, no hyperpigmentation, low ACTH due to hypothalamic-pituitary-adrenal axis suppression)
Haemochromatis
Hyperthyroidism
Anorexia nervosa
129
adrenal insufficiency management
oral glucocorticoid and mineralocorticoid on diagnosis
| Adrenal crisis should be immediately treated with IV hydrocortisone
130
adrenal insufficiency monitoring
monitor plasma renin and potassium
glucocorticoid adjustments made according to signs and symptoms
long term over-replacement of glucocorticoids may be associated with lower bone density
131
adrenal insufficiency complications
secondary Cushing's syndrome
Osteopenia/osteoporosis
Treatment-related HTN
132
adrenal insufficiency prognosis
therapy for life, good compliance
133
diabetes insipidus definition
diabetes insipidus (DI) is a metabolic disorder characterised by an absolute or relative inability to concentrate urine, resulting in the production of large quantities of dilute urine
134
diabetes insipidus aetiology
Two types: central diabetes insipidus (DI), due to reduced synthesis or release of AVP from hypothalamo-pituitary axis; and nephrogenic DI, due to renal insensitivity to AVP
135
diabetes insipidus risk factors
Central: pituitary surgery, craniopharyngioma, traumatic brain injury, hypothalamus-pituitary defects, autoimmune disorders
Nephrogenic: lithium therapy, CKD, chronic hypercalcaemia or hypokalemia
Genetic mutations responsible for inherited forms
136
diabetes insipidus pathophysiology
AVP is the key regulator of renal water loss. Lack of AVP (or its effects) leads to increased diuresis and water loss
137
diabetes insipidus key presentations
polyuria
polydipsia
dehydration
138
diabetes insipidus 1st line investigations
water deprivation test - used to confirm DI. Patient deprived of fluids for 8 hrs. Result is inappropriately low urine osmolality with corresponding high serum osmolality (failure to concentrate urine in response to dehydration).
Desmopressin stimulation test - used to distinguish between central and nephrogenic DI following water deprivation. Patients with central DI respond to desmopressin with a reduction in urine output and increased urine osmolality. Patients with nephrogenic DI do not respond to desmopressin with no or little urine reduction and no increase in urine osmolality
139
Diabetes insipidus management
Central DI: desmopressin
Nephrogenic DI: Bendroflumethiazide (thiazides can create mild hypovolemia which can encourage salt and water uptake in the proximal tubule), NSAIDs (can reduce urinary frequency)
140
Diabetes insipidus complications
Hypernatraemia
141
Syndrome of inappropriate secretion of ADH (SiADH) definition
Syndrome of inappropriate antidiuretic hormone (SIADH) is defined as euvolemic, hypotonic hyponatremia secondary to impaired free water excretion, usually from excessive arginine vasopressin (AVP) release.
Characterised by hypotonic hyponatremia, concentrated urine and a euvolemic state
142
SiADH aetiology
Excess ADH (AVP) leads to increased water reabsorption in the collecting tubule. Resulting concentrated urine with free water intake in excess of what can be excreted leads to hyponatremia
143
SiADH key presentations
cerebral oedema (associated with nausea, vomiting, headache, altered mental status, seizure and coma)
Concentrated urine
Weight loss and confusion
144
SiADH 1st line investigations
Serum osmolality: SiADH presents with hypotonic hypernatremia (low serum sodium and osmolality)
Urine osmolality: high osmolality in presence to low serum sodium and low serum osmolality
Serum urea: usually low due to mild volume expansion
Serum sodium: hyponatremia
Pseudohyponatremia can occur due to hyperglycaemia-induced water shift
145
SiADH management
Treat underlying cause
Fluid restriction
Vasopressin receptor antagonist (captains such as conivaptan or tolvaptan)
146
Hyperkalemia definiton
Significant hyperkalemia defined at serum potassium >6.0mmol/L
Moderate hyperkalemia defined as serum potassium 5.0-6.0mmol/L
147
Hyperkalemia aetiology
Intake issues: hyper due to excessive consumption at a fast rate - IV fluids
Excretion issues:
- low secretion due to low aldosterone (adrenal insufficiency)
- ACE inhibitor (block the binding of aldosterone to receptor)
- acute kidney injury (declined filtration rate so more K+ maintained in blood)
Combination of ACE inhibitors with potassium sparing diuretics or NSAIDs is particularly dangerous in causing hyperkalemia
148
Hyperkalemia pathophysiology
Insulin and beta-agonists facilitate the cellular entry of K+. Insulin deficiency and beta blockers can be followed by a rise in serum potassium values.
Metabolic acidosis can be marked by a shift of potassium from an intracellular to an extracellular location un exchange for H+ ions.
149
Hyperkalemia key presentations
Severe hyperkalemia often present with muscle weakness and evident on ECG. Usually asymptomatic if mild.
Detailed history important
150
Hyperkalemia signs and symptoms
Hyper 'everything speeds up'
- cramping
- weakness/flaccid paralysis due to over contraction of muscles which become drained of energy
- arrhythmias and arrest
151
Hyperkalemia 1st line investigations
U&Es
| ECG
152
Hyperkalemia management
Non-urgent: polystyrene sulphonate resin = binds K+ in gut decreasing uptake
Urgent:
- calcium gluconate = decreases VF risk in the heart
- insulin with glucose = drives K+ into cells
153
Hypokalemia definition
Defined as serum potassium <3.5mmol/L
Moderate hypokalemia defined as 2.5-3.0mmol/L
Severe hpokalemia defined as <2.5mmol/L
154
Hypokalemia aetiology
```
Intake issues:
- fasting, anorexia
- vomiting
Excretion issues:
- high excretion due t high aldosterone
```
155
Hypokalemia pathophysiology
```
Too much K+ follows insulin into cell
Alkalosis H+ out and K+ into cell
B2 agonists (SABA/LABA) increases B2 pumping of K+ into cell
Low K+ into serum (ECF) causes a water concentration gradient out of the cell (ICF). Increased leakage from the ICF causing hyperpolarization of the myocyte membrane decreasing myocyte excitability
```
156
Hypokalemia key presentations
Usually asymptomatic
157
Hypokalemia signs and symptoms
Hypo-everything slows
Constipation
Weakness/cramps
Arrhythmias and palpitations
158
Hypokalemia 1st line investigations
U&Es
ECG
- U have no POT (K+) and not Tea but long PR and a long QT
U wave present, no T waves/inversion, long PR and long QT
- Associated with increased ectopic beats
159
Hypokalemia management
Mild: dietary improvement or oral K+
Severe: IV K+
160
Pheochromocytomas definition
Adrenal medullary tumour that secretes catecholamines
161
Pheochromocytomas epidemiology
Very rare
162
Pheochromocytomas aetiology
Occur in certain familial syndromes:
- multiple endocrine neoplasia (MEN) syndrome
- neurofibromatosis
- Von-Hippel Lindau disease
163
Pheochromocytomas risk factors
family history
164
Pheochromocytomas pathophysiology
Pheochromocytomas synthesise and secrete catecholamines namely: adrenaline, noradrenaline and rarely dopamine. These are converted into metanephrines and normetanephrines. Symptoms caused are due to tumour hypersecretion of catecholamines and increased stimulation of alpha and beta-adrenergic receptors
165
Pheochromocytomas signs and symptoms
Symptoms:
- headache
- profuse sweating (diaphoresis)
- palpitations
- tremor
Signs:
- HTN
- Postural hypotension
- Tremor
- Hypertensive retinopathy
- Pallor
166
Pheochromocytomas 1st line investigations
Plasma metanephrines and normetanephrines (raised)
24 hr urinary total catecholamines (raised)
CT - look for tumour
167
Pheochromocytomas differential diagnosis
Symptomatic phases are are episodic rather than situational
Hyperthyroidism is an important DDx
Carcinoid syndrome: this is associated with dry skin flush rather than pallor
168
Pheochromocytomas management
Without HTN crisis:
- 1st line: alpha blockers: phenoxybenzamine
- Most patients will get tumour removed and then managed medically
With HTN crisis:
- 1st line: antihypertensive agents: phentolamine
169
Pheochromocytomas prognosis
Very good if benign tumour, bad if metastatic
170
Hypercalcaemia definition
Calcium levels >2.6 mmol/L
171
Hypercalcaemia epidemiology
Hypercalcaemia much more common than hypo
| Hypercalcaemia occurs in 20-30% of cancer patients
172
Hypercalcaemia aetiology
```
Malignancies (not in the parathyroid)
Primary hyperparathyroidism (adenoma of the parathyroid gland(s)) (main cause)
Drugs: thiazides, over-the-counter antacids, large doses of vitamin D
```
173
Hypercalcaemia pathophysiology
Serum calcium levels are mainly controlled by parathyroid hormone (PTH) and vitamin D.
Malignancies secreting parathyroid hormone related peptide (PTHrP), bony metastases promoting osteoclast differentiation and function, calcitriol secretion by lymphoma cells
174
Hypercalcaemia key presentations
Mild is usually asymptomatic
175
Hypercalcaemia signs and symptoms
Bones, stones, moans, groans
Bone pain, osteoporosis
Kidney stones
Abdominal moans (pain, constipation, acute pancreatitis)
Psychic groans (confusions, insomnia, anxiety, cognitive dysfunction)
Weakness, fatigue, muscle symptoms, polyuria, polydipsia
176
Hypercalcaemia 1st line investigations
Bloods: raised Ca++, decreased K+, alkalosis, decreased Cl-, decreased albumin
24hr urinary Ca++
Malignancy causes - low albumin, low PTH (tumour secreting PTHrP not PTH)
177
Hypercalcaemia management
Acute severe hypercalaemia is a medical emergency
Aggressive rehydration - IV 0.9% saline
Bisphosphates (pamidronate)
Oral prednisolone
178
Hypocalcaemia aetiology
Renal failure is the most common cause (due to increased phosphate levels)
Hypocalcaemia after thyroid or parathyroid surgery (usually short lasting)
179
Hypocalcaemia signs and symptoms
```
Tetany (muscle spasms)
Neuropsychiatric signs (convulsions, psychosis, anxiety)
```
180
Hypocalcaemia 1st line investigations
Serum and urine creatinine (renal disease)
PTH levels - absent or low in hypoparathyroidism, high in other causes 25-hydroxyvitamin D levels for suspected vitamin D deficiency
181
Hypocalcaemia management
Vitamin D derivatives (alpha-hydroxylates are preferred)
| Treat underlying cause
182
Carcinoid syndrome definition
Groups of symptoms due to release of seritonin and other vasoconstriction peptides into systemic circulation from carcinoid tumour. Carcinoid tumours are neuroendocrine tumours often in the midgut
183
Carcinoid syndrome aetiology
Caused by carcinoid tumours. Very common in patients with liver metastasis
184
Carcinoid syndrome pathophysiology
increased serotonin and other products go directly into systemic circulation and cause the symptoms
185
Carcinoid syndrome signs and symptoms
Symptoms:
- diarrhoea
- flushing
Signs:
- palpitations
- abdonimnal cramps
- signs of right heart failure
- bronchospasm
186
Carcinoid syndrome 1st line investigations
High volume of urinary 5-hydroxyindoleacetic acid (breakdown product of serotonin)
Metabolic panel and LFTs
Liver ultrasound: confirm metastases
187
Carcinoid syndrome differential diagnosis
IBC
Crohn's
Menopause
In all of these there will be a normal 5-hydroxyindoleacetic acid
188
Carcinoid syndrome management
Local disease: surgical resection + peri-operative octreotide infusion
Metastases: above + additional radiofrequency ablation
